NEOADJUVANT TREATMENT OF HER2-POSITIVE BREAST CANCER


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

A number of international clinical trials involving Russian oncological centers have justified broad prospects for dual blockade of HER2-positive breast cancer as the metastatic process and during neoadjuvant therapy including anthracyclines and taxanes in combination with pertuzumab and trastuzumab. The antitumor activity of the Russian combined drug «pertuzumab+trastuzumab» (Beyodim) is confirmed by increase in relapse-free and overall survival.

Texto integral

Acesso é fechado

Sobre autores

V. Semiglazov

FSBI "SRI of Oncology n.a. N.N. Petrov" of RMPH

Email: vsemiglazov@mail.iu
MD, Prof., Honored Scientist, Corresponding Member of RAS, Head of the Scientific Department of Bieast Tumors, Chief Researcher St.-Petersburg

V. Semiglazov

St. Petersburg State Medical University n.a. Acad. I.P. Pavlov of RMPH

St.-Petersburg

G. Dashyan

FSBI "SRI of Oncology n.a. N.N. Petrov" of RMPH

St.-Petersburg

P. Krivorotko

FSBI "SRI of Oncology n.a. N.N. Petrov" of RMPH

St.-Petersburg

K. Nikolaev

FSBI "SRI of Oncology n.a. N.N. Petrov" of RMPH

St.-Petersburg

T. Semiglazova

FSBI "SRI of Oncology n.a. N.N. Petrov" of RMPH

St.-Petersburg

A. Komyakhov

St. Petersburg State Medical University n.a. Acad. I.P. Pavlov of RMPH

St.-Petersburg

A. Bessonov

FSBI "SRI of Oncology n.a. N.N. Petrov" of RMPH

St.-Petersburg

R. Donskikh

FSBI "SRI of Oncology n.a. N.N. Petrov" of RMPH

St.-Petersburg

R. Paltuev

FSBI "SRI of Oncology n.a. N.N. Petrov" of RMPH

St.-Petersburg

K. Zernov

FSBI "SRI of Oncology n.a. N.N. Petrov" of RMPH

St.-Petersburg

Bibliografia

  1. Семиглазов В.Ф., Семиглазов В.В. Рак молочной железы: биология, местное и системное лечение. М, 2014. 352 с.
  2. Cortazar P., Zhang L., Untch M., Mehta K., Costantino J.P., Wolmark N., Bonnefoi H., Cameron D., Gianni L., Valagussa P., Swain S.M., Prowell T., Loibl S., Wickerham D.L., Bogaerts J., Baselga J., Perou C., Blumenthal G., Blohmer J., Mamounas E.P., Bergh J., Semiglazov V., Justice R., Eidtmann H., Paik S., Piccart M.,Sridhara R., Fasching P.A., Slaets L., Tang S., Gerber B., Geyer C.E. Jr, Pazdur R., Ditsch N., Rastogi P., Eiermann W., von Minckwitz G. Pathological complete response and long term clinical benefit in breast cancer: the CTNEOBC pooled analysis. Lancet. 2014;384: 164-72.
  3. Rastogi P., Anderson S.J., Bear H.D., Geyer C.E., Kahlenberg M.S., Robidoux A., Margolese R.G., Hoehn J.L., Vogel V.G., Dakhil S.R., Tamkus D., King K.M.,PajonE.R, WrightM.J.,RobertJ.,PaikS, Mamounas E.P., Wolmark N. Preoperative chemotherapy updates of National Surgical Adjuvant Breast and Bowel Project Protocol B-18 and B-27. J. Clin. Oncol. 2008;26:778-85.
  4. Gianni L., Eiermann W., Semiglazov V., Manikhas A., Lluch A., Tjulandin S., Zambetti M., Vazquez F., Byakhow M., Lichinitser M., Cli-ment M.A., Ciruelos E., Ojeda B., Mansutti M., Bozhok A., Baronio R., Feyereislova A., Barton C., Valagussa P., Baselga J. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010; 375:377-84.
  5. Semiglazov V., Eiermann W., Zambetti M., Manikhas A., Bozhok A., Lluch A., Tjulandin S., Sabadell M.D., Caballero A., Valagussa P., Baselga J., Gianni L. Surgery following neoadjuvant therapy in patients with HER2 - positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study. Eur J Surg Oncol. 2011;37(10):856-63.
  6. Gianni L., Pienkowski T., Im Y.H., Roman L., Tseng L.M., Liu M.C., Lluch A., Staroslawska E., de la Haba-Rodriguez J., Im S.A., Pedrini J.L., Poirier B., Morandi P., Semiglazov V., Srimuninnimit V., Bianchi G., Szado T., Ratnayake J., Ross G., Valagussa P. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012; 13:25-32.
  7. U.S. Food and Drug Administration. FDA approves Perjeta for neoadjuvant breast cancer treatment. http://www. fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm370393. htm. Accessed March 3, 2015.
  8. Gradishar W.J., Anderson B.O., Blair S.L., Burstein H.J., Cyr A., Elias A.D., Farrar W.B., Forero A., Giordano S.H., Goldstein L.J., Hayes D.F., Hudis C.A., Isakoff S.J., Ljung B.M., Marcom P.K., Mayer I.A., McCormick B., Miller R.S., Pegram M., Pierce L.J., Reed E.C., Salerno K.E., Schwartzberg L.S., Smith M.L., Soliman H., Somlo G., Ward J.H., Wolff A.C., Zellars R., Shead D.A., Kumar R.; National Comprehensive Cancer Network Breast Cancer Panel. Breast Cancer Version 3. J. Natl. Compr. Canc. Netw. 2015;13(4):448-75.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2016